Anebulo Pharmaceuticals (ANEB) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
7 Jan, 2026Opening remarks and agenda
CEO called the 2025 Annual Stockholders' Virtual Meeting to order at 12:00 P.M. EST on April 4, 2025, and introduced the Board members present.
CFO Dan George was introduced as Secretary of the Meeting, and independent auditors and the Inspector of Elections were acknowledged.
Board and executive committee updates
Board members present included Joseph Lawler (Chairman), Areta Kupchyk, Nathaniel Calloway, and Bimal Shah, with their respective tenures noted.
Shareholder proposals
Six proposals were presented: Board declassification, election of directors, increase in authorized shares, amendment to Stock Incentive Plan, ratification of auditors, and removal of voting restrictions on certain shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Anebulo Pharmaceuticals
- Net loss improved, cash remains strong, and IV selonabant for pediatric use is prioritized amid delisting.ANEB
Q2 2026 - Registers 15.15M shares for resale after $15M private placement, shifting control to a major holder.ANEBRegistration Filing
- Reverse stock split proposed to go private, cashing out small holders at $3.50 per share.ANEBProxy Filing
- Reverse split and cash-out plan aims to go private, delist, and cut public company costs.ANEBProxy Filing
- Board seeks approval for declassification, share increases, and key governance changes.ANEBProxy Filing
- Shareholders will vote on a reverse split to go private, cashing out small holders at $3.50 per share.ANEBProxy Filing
- Six key proposals—including board declassification and share increases—are up for shareholder vote.ANEBProxy Filing
- Phase 1 IV selonabant study launched for pediatric cannabis toxicity; Q1 net loss $2.2M.ANEBQ1 2026
- IV selonabant for pediatric cannabis toxicity advances, with higher expenses and ongoing strategic review.ANEBQ4 2025